

# Introduction of human pharmaceuticals from wastewater treatment plants into the aquatic environment: a rural perspective

Carolina Nebot · Raquel Falcon · Kenneth G. Boyd · Stuart W. Gibb

Received: 9 December 2014 / Accepted: 13 February 2015 / Published online: 5 March 2015  
© Springer-Verlag Berlin Heidelberg 2015

**Abstract** Incomplete removal of pharmaceuticals during wastewater treatment can result in their discharge into the aquatic environment. The discharge of pharmaceuticals in wastewater treatment plant (WWTP) effluents into rivers, lakes and the oceans has led to detectable concentrations of pharmaceuticals in the aquatic environment in many countries. However, to date studies of WWTP discharges into the aquatic environment have largely been confined to areas of relatively high population density, industrial activity or systems impacted on by such areas. In this work, two sites in the far north of Scotland were used to assess whether, and which, pharmaceuticals were being introduced into natural waters in a rural environment with low population density. Samples from two WWTPs (with differing modes of operation), and one receiving water, the River Thurso, were analysed for the presence of 12 pharmaceuticals (diclofenac, clofibric acid, erythromycin, ibuprofen, mefenamic acid, paracetamol, propranolol, sulfamethoxazole, tamoxifen, trimethoprim and dextropropoxyphene). Ten of the 12 pharmaceuticals investigated were detected in at least one of the 40 WWTP effluent samples. Maximum concentrations ranged from 7 ng L<sup>-1</sup> (sulfamethoxazole) to 22.8 µg L<sup>-1</sup> (paracetamol) with

diclofenac and mefenamic acid being present in all of samples analysed at concentrations between 24.2 and 927 ng L<sup>-1</sup> and 11.5 and 22.8 µg L<sup>-1</sup>, respectively. Additionally, the presence of four pharmaceuticals at ng L<sup>-1</sup> levels in the River Thurso, into which one of the WWTPs discharges, shows that such discharges result in measurable levels of pharmaceuticals in the environment. This provides direct evidence that, even in rural areas with low population densities, effluents from WWTPs can produce quantifiable levels of human pharmaceutical in the natural aquatic environment. These observations indicate that human pharmaceuticals may be considered as contaminants, with potential to influence water quality, management and conservation not only in urban and industrial regions but also those more rural in nature.

**Keywords** Pharmaceuticals · Wastewater · Rural areas · River water

## Introduction

Pharmaceuticals are now an important and indispensable part of modern society being employed in human and veterinary medicine, agriculture and aquaculture (Dietrich et al. 2002). In the UK alone, more than 3,000 active ingredients are licenced for use as human pharmaceuticals while the number of prescriptions and number of individual chemical entities involved increases every year; for example, the number of prescription items dispensed in Scotland increased 31.8 % between 2004/05 and 2013/14 (NHS 2014).

Following administration, human pharmaceuticals may be excreted, either in their original form or as metabolites, before being introduced into the domestic wastewater system (Andreozzi et al. 2003). The incomplete removal of pharmaceuticals during wastewater treatment may result in their

---

Responsible editor: Leif Kronberg

C. Nebot · K. G. Boyd · S. W. Gibb  
Environmental Research Institute, North Highland College,  
University of the Highlands and Islands, Castle Street, Thurso,  
Caithness, Scotland KW14 7JD, UK

C. Nebot (✉)  
Department of Analytical Chemistry, Nutrition and Bromatology,  
Faculty of Veterinary Medicine, University of Santiago de  
Compostela, 27002 Lugo, Spain  
e-mail: carolina.nebot@usc.es

R. Falcon  
University of Portsmouth, University House, Winston Churchill  
Avenue, Portsmouth PO1 2UP, UK

discharge into the aquatic environment. The first report of human pharmaceuticals in effluents collected from wastewater treatment plants (WWTPs) identified clofibric acid (a metabolite of the blood lipid regulator clofibrate) at concentrations of between 0.8 and 2  $\mu\text{g L}^{-1}$  (Garrison et al. 1976). Subsequent studies have demonstrated the presence of pharmaceuticals in wastewaters and their receiving waters in countries around the world, including Italy (Andreozzi et al. 2003; Zuccato et al. 2004, 2008), Japan (Nakada et al. 2006), USA (Brown et al. 2006), Germany (Ternes 1998; Heberer et al. 2001), Spain (Carballa et al. 2007; Farre et al. 2001), Canada (Gagne et al. 2006), Sweden (Andreozzi et al. 2003; Lindberg et al. 2006), England (Hilton et al. 2003) and Wales (Kasprzyk-Hordern et al. 2008; Baker and Kasprzyk-Hordern 2013; Barbara et al. 2008). In general, these studies have been conducted in wastewater treatment plants located in large cities which serve a population higher than 10,000 inhabitants in addition to industrial discharge.

The investigation of pharmaceuticals in WWTP influent and effluent samples has also been used to calculate the removal efficiencies during the treatment process. For example, Bendz et al. (2005) reported 49 and 97 % removal of the antibiotic trimethoprim in two different WWTPs in Germany. Similarly, Jones et al. (2007) investigated the removal of paracetamol, mefenamic acid and ibuprofen in a WWTP located in the south of England. Results indicated that while elimination rates were ~90 % for each compound, they were still present at concentrations of several hundred  $\text{ng L}^{-1}$  in the final effluent discharged into the receiving waters. The consequence is that pharmaceuticals are being discharged continuously into the aquatic environment of many countries including Italy (Zuccato et al. 2005), Romania (Moldovan 2006), Germany (Ternes et al. 2001), Japan (Nakada et al. 2007), China (Zhao et al. 2010; Sui et al. 2012) and Canada (Metcalf et al. 2003). The potential effects of these substances in the aquatic environment have also been investigated (Boxall et al. 2004; Corcoran et al. 2010; Kools et al. 2008; Kümmerer 2008, 2009; Sanderson et al. 2007; Kemper 2008; Sarmah et al. 2006).

Scotland has a population of approximately 5,100,000 inhabitants within a total area of 77,925  $\text{km}^2$ . A considerable proportion of the population live in rural areas, with population densities less than 1,000 per  $\text{km}^2$ . The largest cities in Scotland are Glasgow (3,378 inhabitants per  $\text{km}^2$ ), Dundee (2,412 inhabitants per  $\text{km}^2$ ), Edinburgh (1,843 inhabitants per  $\text{km}^2$ ) and Aberdeen City (1,169 inhabitants per  $\text{km}^2$ ) which have a total combined area of 685  $\text{km}^2$  representing approximately 1 % of the total Scottish land area (The Office for National Statistics 2013). In these locations, domestic, industrial and hospital discharges are potential sources of pharmaceuticals. However, most of Scotland supports a population density of less than 100 inhabitants per  $\text{km}^2$ . Considering the fact that to date the detection of pharmaceuticals in the environment and in WWTP discharges has been

largely limited to areas with relatively high population densities or sites impacted on by such areas, there is a need to investigate the presence of these substances in rural areas and in wastewater effluent of WWTPs which serve populations lower than 10,000.

This paper seeks to test the hypothesis that even in rural areas with low population densities, WWTPs can be the source of quantifiable levels of pharmaceuticals in the natural aquatic environment.

Employing an HPLC-MS/MS method for the analysis of 12 pharmaceuticals reported previously, we report results from a study conducted in the far North of Scotland which has one of the lowest population densities in Europe. The study was conducted in Caithness situated in the far north of the mainland UK; it has a population of 25,160, an area of 1,844  $\text{km}^2$  and this has a population density of 14 inhabitants per  $\text{km}^2$ . This provides an initial assessment of whether (and which) pharmaceuticals may be introduced into the natural aquatic environment in a rural area with low population density and low industrial intensity.

## Materials and methods

### Chemicals and standards

Methanol (HPLC-grade) and acetone (glass-distilled grade) were obtained from Rathburn Chemicals Ltd. (Walkerburn, UK); hydrochloric acid (HCl, AR grade), ammonia solution 28–30 % (GR for analysis ACR) and acetic acid (GPR grade) from VWR International (Lutterworth, UK); and ammonium acetate (GR for analysis ACR) from Merck Pharmaceuticals (West Drayton, UK). Diclofenac (sodium salt), clofibric acid, erythromycin, ibuprofen, mefenamic acid, paracetamol, ( $\pm$ )-propranolol hydrochloride, sulfamethoxazole, tamoxifen and trimethoprim were obtained from Sigma-Aldrich Co. Ltd. (Dorset, UK). Dextropropoxyphene hydrochloride was obtained from British Pharmacopoeia Commission Laboratory (Teddington, UK). All compounds were of a purity >95 %. Milli-Q water was used unless otherwise stated.

Standard solutions were prepared in a 50:50 (v/v) mix of methanol: 10 mM ammonium acetate at pH 6 (pH was regulated using 0.1 M HCl). Standards of concentration <2,000  $\mu\text{g L}^{-1}$  were prepared every 3 months and those >2,000  $\mu\text{g L}^{-1}$  every 6 months. All standards were stored in the dark at  $-18^\circ\text{C}$ . Standard solutions containing 20  $\text{mg L}^{-1}$  of individual pharmaceuticals were diluted to give individual standard solutions at concentrations of 250 and 1,000  $\mu\text{g L}^{-1}$  for MS tuning and HPLC optimization. Standard solutions of individual compounds (20  $\text{mg L}^{-1}$ ) were mixed to obtain mixed standard solutions containing all pharmaceuticals at concentrations of 1, 2, 10, 50, 200 and 250  $\mu\text{g L}^{-1}$ , which were employed for calibration.

## Equipment

The HPLC-MS/MS system consisted of an Alliance 2695 HPLC (Waters; Manchester, UK) coupled to a Micromass® Quattro Micro™ detector with electrospray ionisation (ESI). Data acquisition and control were carried out using Masslynx™ NT software (Waters; Milford, MA, USA).

Analytes were separated on a 250 mm×2 mm C<sub>18</sub> Luna® column (10 µm particle size; Phenomenex; Macclesfield, UK) used in conjunction with a 4.0 mm×2.0 mm C<sub>18</sub> guard column (Phenomenex).

Evaporation of extracts was performed with a turbo-evaporator (Turbo Vap® II, Zymark, Hopkinton, MA, USA) using nitrogen gas (supplied by a nitrogen generator; In House Gas, Killearn, UK) model N<sub>2</sub>MaxiFlow 60 L (purity 99 %).

Statistical analysis of the data was conducted with the software package STATGRAPHICS Centurion XVI version 16.1.11 64-bits (StatPoint Technologies, Inc. Warrenton, Virginia, USA).

## Sample sites and collection

### *WWTPs characteristics*

Two WWTPs, designated WWTP 1 and 2, in a region of relatively low population density (see above) were selected for this study. WWTP 1 serves a village of approximately 950 inhabitants and additionally treats sewage sludge from septic tanks from a wider area of approximately 1,844 km<sup>2</sup>. Treated effluent is discharged into the River Thurso downstream of the village. The cycle time of this plant is highly dependent on levels of precipitation.

WWTP 2 serves a population of approximately 7,000 inhabitants including the main hospital for the area which serves a population of 35,000. In this WWTP, the cycle takes approximately 9 h but is also dependant on levels of precipitation.

Effluent samples for the determination of pharmaceuticals were collected from WWTP1 over five separate 5-day periods: the 18th to the 22nd of July 2005 (week 1), the 10th to the 14th of October 2005 (week 2), the 12th to the 16th of December 2005 (week 3), the 19th to the 23rd of June 2006 (week 4) and the 26th to the 30th of June 2006 (week 5). From WWTP, two samples were collected over three separate 5-day periods, corresponding to weeks 1, 3 and 5 above.

### *River characteristics*

In order to investigate possible impacts of the discharge of pharmaceuticals from a WWTP on a natural watercourse, samples were collected from the River Thurso into which the WWTP 1 discharges treated water. The River Thurso runs through the county of Caithness in the northern Highlands of Scotland and drains a predominantly peatland catchment of

412.8 km<sup>2</sup>. It flows north through a short section of agricultural land before entering the Pentland Firth at the town of Thurso. The mean river flow is 8,980 L s<sup>-1</sup> and the average rainfall in the area is 1,057 mm (SEPA 2007c).

River water samples were collected at four points along the river: ‘upstream’ (0.05 km from WWTP 1 discharge point); ‘downstream 1’ (0.1 km from the discharge point), ‘downstream 2’ (12.80 km from the discharge point), ‘downstream 3’ (14.70 km from the discharge point). River water samples were collected during weeks 2 (10–14 October 2005) and 4 (19–23 June 2006) (as specified above) between 9 and 11 a.m.

### *Sample collection*

Prior to collection, sample vessels and collecting apparatus were rinsed three times with the waters being sampled. Samples were collected using an extendable sampling pole and transferred into individual, labelled 2.5-L amber glass bottles and stored in a cool box for transportation to the laboratory. On returning to the laboratory, samples were either processed immediately or stored at 5 °C prior to processing. In all cases, samples were processed within 5 h of collection.

### *Sample extraction and analysis*

Samples were processed as described by Nebot et al. (2007). Briefly, 2 L of each sample was filtered through a GF/F microfibre filter (Whatman; Middlesex, UK) using a positive pressure filtration system (Vernon Hills, Illinois). After filtration, the pH of the 2.0-L sample was adjusted to 6. Pharmaceuticals were extracted using SPE Strata™X cartridges. The eluate was collected in a glass tube and evaporated to 0.1 mL at 55 °C. The volume was then made up to 0.3 mL with 50:50 mix of methanol: 10 mM ammonium acetate at pH 6, transferred to amber auto-sampler vials (2 mL, containing 0.5 mL insert vials) and stored at -18 °C prior to analysis by HPLC-MS/MS. Blank and fortified samples (1 µg L<sup>-1</sup>) were processed with each batch of samples.

Two HPLC methods were used for the analysis of the selected pharmaceuticals. The first (method A) was used for the analysis of paracetamol, trimethoprim, sulfamethoxazole, propranolol, erythromycin, dextropropoxyphene, tamoxifen, diclofenac and mefenamic acid and the second (method B) for ibuprofen and clofibrac acid. Both methods used water, methanol, ammonium acetate (10 mM, adjusted to pH 6.0 with 0.1 M HCl) and acetic acid (0.87 M) as mobile phase components. The flow rates were 0.17 mL min<sup>-1</sup> (method A) and 0.2 mL min<sup>-1</sup> (method B). Auto-sampler tray and column heater temperatures were maintained constant during the analysis at 5 and 25 °C, respectively. The injection volume was 30 µL.

Positive ionisation was used for method A and negative for method B. In both, the following general parameters were

applied: Extractor voltage, 2.20 V; radio frequency lens, 0.20 V; source temperature, 120 °C; low mass (LM) 1 resolution, 12.70; high mass (HM) 1 resolution 1, 12.70; ion energy 1, 0.40; entrance, 0.00; exit, 1.00; LM 2 resolution, 13.20; HM 2 resolution 1, 13.20; ion energy 2, 1.00; multiplier, 650.00 V. Method A utilised a capillary voltage of 3.20 kV, desolvation temperature of 400 °C, cone gas flow of 71.00 L h<sup>-1</sup> and desolvation gas flow of 420.00 L h<sup>-1</sup>. Method B utilised a capillary voltage of 1.20 kV, desolvation temperature of 200.0 °C, cone gas flow of 30.00 L h<sup>-1</sup> and desolvation gas flow of 256.00 L h<sup>-1</sup>.

Table 1 shows the LOD and LOQ of the pharmaceuticals in river and effluent samples following the protocol described above.

## Results and discussion

### WWTP samples

A total of 40 effluent samples, 25 from WWTP 1 and 15 from WWTP 2, were collected during the study. The frequency of detection of each compound along with the mean and maximum concentrations and the percentage residual standard deviation of each are presented in Table 2 and the mean, maximum and minimum concentrations are shown in Fig. 1. The concentrations of the pharmaceuticals detected in each sample are provided as supplemental information.

### Pharmaceuticals in WWTP Effluents

With pharmaceuticals being detected in the effluents collected from both WWTPs, it is clear that pharmaceuticals are discharged into the environment by the two plants at these

**Table 1** LOD and LOQ (ng L<sup>-1</sup>) of the pharmaceuticals for river (*r*) and effluent (*e*) samples

	River		Effluents	
	LODr (ng L <sup>-1</sup> )	LOQr (ng L <sup>-1</sup> )	LODe (ng L <sup>-1</sup> )	LOQe (ng L <sup>-1</sup> )
Paracetamol	3.9	13.1	10.9	36.7
Trimethoprim	0.1	0.3	0.1	0.3
Sulfamethoxazole	0.1	0.4	0.2	0.7
Propranolol	0.1	0.4	0.1	0.4
Erythromycin	0.1	0.3	0.1	0.5
Dextropropoxyphene	0.0	0.1	0.2	0.7
Tamoxifen	0.1	0.3	0.1	0.5
Diclofenac	0.2	0.6	0.2	0.5
Mefenamic acid	0.1	0.3	0.1	0.3
Ibuprofen	1.0	3.2	1.1	3.7
Clofibrac acid	4.8	16.1	7.1	23.9

locations. While this is the first report of the direct quantification of the discharge such substances into Scottish waters, their presence in the WWTP effluents has been reported in numerous other countries; including Sweden (Bendz et al. 2005), Japan (Nakada et al. 2007), Spain (Gros et al. 2006; Carballa et al. 2004), Canada (Gagne et al. 2006), Italy (Andreozzi et al. 2003), Switzerland (Maurer et al. 2007), France (Andreozzi et al. 2003; Rabiet et al. 2006) and England (Ashton et al. 2004; Roberts and Thomas 2006; Hilton and Thomas 2003).

Over the course of the study, the most frequently detected pharmaceuticals were diclofenac, mefenamic acid, ibuprofen, propranolol and trimethoprim with each being found in over 80 % of the samples analysed (Table 2). Diclofenac and mefenamic acid were detected in all of the samples analysed with the concentration of diclofenac ranging from 24.2 to 927 ng L<sup>-1</sup> and those of mefenamic acid from 10.7 to 1,327 ng L<sup>-1</sup>. (Fig. 1). The mean concentrations of diclofenac and mefenamic acid were 172 and 280 ng L<sup>-1</sup>, respectively. Ibuprofen was detected in all but one of the samples (97 %), with a mean concentration of 278 ng L<sup>-1</sup> and a maximum concentration of 2,026 ng L<sup>-1</sup>. Propranolol and trimethoprim were detected in 84 and 88 % of the samples, respectively. Propranolol had a mean concentration of 142 ng L<sup>-1</sup> and maximum concentration of 773 ng L<sup>-1</sup>. Trimethoprim had a mean concentration of 266 ng L<sup>-1</sup> with maximum concentration of 969 ng L<sup>-1</sup>.

The next most commonly detected pharmaceuticals were dextropropoxyphene, erythromycin and paracetamol measured in 50–75 % of all samples analysed. Dextropropoxyphene and erythromycin were found in 52 and 55 % of samples, respectively. The concentration of dextropropoxyphene ranged from below the limit of detection to 203 ng L<sup>-1</sup>, with a mean value of 34 ng L<sup>-1</sup>. In the case of erythromycin, the concentration ranged from below the limit of detection to 2.5 µg L<sup>-1</sup>, with a mean concentration of 381 ng L<sup>-1</sup>. The concentration of paracetamol ranged from less than the limit of detection to 22.8 µg L<sup>-1</sup>, the highest concentration of any of the compounds detected.

It may be noted that paracetamol is not commonly included in suites of compounds targeted for analysis WWTP effluents. However, concentrations in excess of 0.5 µg L<sup>-1</sup> have been reported in river water in the UK (Bound and Voulvoulis 2006), suggesting that discharges of the magnitude observed in this work may not be unexpected.

Similar high concentrations of erythromycin have been found in effluents collected from WWTPs in Canada (Miao and Metcalfe 2003) and England (Ashton et al. 2004). In contrast, the concentration of erythromycin measured in effluents from a Spanish WWTP was only 1 % of those found here (Gomez et al. 2006). The concentration of erythromycin in final effluents can be reduced by using ozonation, as reported by Nakada et al. (2007); however, UV or sand filtration

**Table 2** Frequency of detection, mean and maximum measured concentrations and percentage residual standard deviation for each pharmaceutical measured in samples collected from two wastewater treatment plants, *n*=40

Pharmaceutical	Frequency of Detection (%)	Mean Concentration (ng L <sup>-1</sup> )	Maximum Concentration (ng L <sup>-1</sup> )	%RSD
Dextropropoxyphene	52	34	203	159
Diclofenac	100	172	927	110
Erythromycin	55	381	2505	138
Ibuprofen	98	278	2206	134
Mefenamic acid	100	280	1327	117
Paracetamol	75	762	22782	464
Propranolol	85	142	773	110
Sulfamethoxazole	2.5	0	7	624
Tamoxifen	10	1	13.4	348
Trimethoprim	88	266	969	91
Clofibric acid		0	0	0

treatments have been shown to be ineffective in removing this compound (Roberts and Thomas 2006 and Nakada et al. 2007).

In contrast, of the pharmaceuticals found, the least frequently detected were sulfamethoxazole, which was found in only one sample, and tamoxifen, which was present in four of the 40 effluent samples collected with a maximum concentration of 13.4 ng L<sup>-1</sup>. Clofibric acid was not detected in any of the effluent samples analysed. In the case of clofibric acid, this is not surprising as it is not dispensed in Scotland. However, it was included in this study as its presence been reported in the North Sea (Weigel et al. 2002; Buser and Müller 1998), which borders the east coast of the county of Scotland in which this work was conducted.

The concentration of individual pharmaceuticals in the effluents varied considerably. Considering all the data, the %RSDs for the concentration of all compounds were greater


than 90 %. The highest %RSD was for paracetamol (464 %). This highly variable concentration of paracetamol in WWTP effluents has previously been reported by Andreozzi et al. (2003) who reported concentrations of ibuprofen ranging from 20 to 1.82 µg L<sup>-1</sup> and diclofenac ranging from 250 to 5.45 µg L<sup>-1</sup>, in effluent samples from France, Italy, Greece and Sweden.

*Comparison of WWTPs effluents*

Comparing the data from the two WWTPs (S1); with the exception of a single occurrence of paracetamol at a concentration of 22.8 µg L<sup>-1</sup>, the concentration range of the selected pharmaceuticals in the effluents collected from both were similar; between <LOD and 2,505 ng L<sup>-1</sup> for effluents collected at WWTP 1 and between <LOD and 1,117 ng L<sup>-1</sup> for those collected at WWTP 2. While, as mentioned above, diclofenac and mefenamic acid were detected in all the samples from both WWTPs, ibuprofen, trimethoprim and propranolol were additionally detected in all of the samples collected from WWTP 2. Other pharmaceuticals with a high frequency of detection in the individual plants were paracetamol, (92 %) in WWTP 1, and erythromycin, (93 %) in WWTP 2. Tamoxifen was only detected in samples taken from WWTP1 with sulfamethoxazole detected in only a single sample, taken from WWTP 2.


In both WWTPs, the pharmaceuticals with the highest mean concentrations (erythromycin and trimethoprim) were not necessarily those that most frequently detected in the overall sample set (i.e. diclofenac and mefenamic acid). The pharmaceutical with the maximum mean concentration in WWTP 1 was erythromycin (422 ng L<sup>-1</sup>) which was detected in 64 % of the effluents. Meanwhile, trimethoprim has the maximum mean concentration in WWTP 2 (352 ng L<sup>-1</sup>) and was detected in all the samples from WWTP 2.

The mean concentrations of the most frequently detected pharmaceuticals (diclofenac, mefenamic acid, ibuprofen,



**Fig. 1** Range of concentrations for pharmaceuticals detected in effluents from two WWTPs. Bars show maximum and minimum values while boxes represent means

**Fig. 2** Comparison of the concentrations of the five most frequently detected pharmaceuticals (diclofenac, mefenamic acid, ibuprofen, propranolol and trimethoprim) in the discharges from the two WWTPs. The top and bottom of each box corresponds to the maximum and minimum concentration, respectively, with the interior horizontal line indicating the mean. The asterisk signifies a significant difference between the concentrations found in the two plants



**Table 3** Concentrations of pharmaceuticals (ng L<sup>-1</sup>) measured in samples taken from the River Thurso

Collection Day	Pharmaceutical	Upstream	Downstream	Weir	Harbour	Average	STDEV	RSD (%)
October sampling period								
10/10/2005	Di	1.9	< LOD	0.5	0.7	0.8	0.8	104
11/10/2005	Di	< LOD	0.5	< LOD	0.7	0.3	0.4	119
12/10/2005	Di	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
13/10/2005	Di	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
14/10/2005	Di	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
10/10/2005	Me	< LOD	< LOD	0.5	0.5	0.3	0.3	115
11/10/2005	Me	< LOD	< LOD	0.3	0.2	0.1	0.2	120
12/10/2005	Me	< LOD	< LOD	0.1	0.1	0.1	0.1	115
13/10/2005	Me	< LOD	< LOD	0.3	< LOD	0.1	0.2	200
14/10/2005	Me	< LOD	0.3	0.3	0.2	0.2	0.1	71
June sampling period								
19/06/2006	Pa	< LOD	3.9	< LOD	< LOD	1.0	2.0	200
20/06/2006	Pa	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
21/06/2006	Pa	9.1	7.2	< LOD	< LOD	4.1	4.8	117
22/06/2006	Pa	< LOD	9.0	< LOD	< LOD	2.3	4.5	200
23/06/2006	Pa	6.4	6.2	< LOD	< LOD	3.2	3.6	115
19/06/2006	Di	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
20/06/2006	Di	0.3	< LOD	< LOD	< LOD	0.1	0.2	200
21/06/2006	Di	< LOD	< LOD	< LOD	0.8	0.2	0.4	200
22/06/2006	Di	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
23/06/2006	Di	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
19/06/2006	Ib	1.3	< LOD	< LOD	< LOD	0.3	0.7	200
20/06/2006	Ib	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
21/06/2006	Ib	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
22/06/2006	Ib	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A
23/06/2006	Ib	< LOD	< LOD	< LOD	< LOD	< LOD	< LOD	N/A

<LOD Below limit of detection in fresh water samples (Di: 0.2 ng L<sup>-1</sup>; Me: 0.1 ng L<sup>-1</sup>; Pa: 3.9 ng L<sup>-1</sup>; Ib: 1.0 ng L<sup>-1</sup>), N/A Not available, SDTEV Standard deviation, Pa paracetamol, Di diclofenac, Ib ibuprofen, Me Mefenamic acid

propranolol and trimethoprim) in the discharges from the two WWTPs were compared. Figure 2 indicates statistically significant differences for propranolol, trimethoprim and ibuprofen ( $p < 0.05$ ; Kolmogorov-Smirnov and Mann-Whitney test) between the two plants. In contrast, no significant difference was noted for both diclofenac and mefenamic acid. The mean concentrations of diclofenac, mefenamic acid, propranolol and trimethoprim were 35, 25, 59 and 49 % higher, respectively, in the effluents from WWTP 2 with the mean concentration of ibuprofen in effluents from WWTP 1 being 60 % higher than that from WWTP 2.

The higher concentrations of the most frequently detected pharmaceuticals in WWTP2 effluents could be due to the fact that WWTP 2 serves a larger population and includes wastewater from a hospital. However, it may also be due to the differences in the treatment processes employed at the two plants i.e. at WWTP1 influent is initially subjected to primary treatment (grit removal, screening bars and settling tank) before being transferred to a trickling biofilter for further treatment. Part of the effluent (approximately 20 %) from the trickling biofilter is transferred back to the settling tank and the remainder sent to a second settling tank where clarifiers are added. Meanwhile, at WWTP 2, the influent receives primary treatment (grit removal, screening and settling) followed by secondary treatment with activated sludge. The plant has two activated sludge tanks which are used in turn in a batch process.

River water samples

Results obtained during the first sampling period (week 1) for effluents from WWTP 1 and 2 demonstrated the presence of


pharmaceuticals and consequently their discharge in to the environment. WWTP 1 discharges its effluent into a local river and WWTP 2 into the North Sea. As monitoring at sea presented logistical issues, a monitoring study was conducted in the River Thurso into which WWTP1 discharges. Results are presented in Table 3.

The river was sampled at a time when lower concentrations of pharmaceuticals may have been expected based on rainfall, temperature and sunlight due to dilution factor or degradation (Castiglioni et al. 2006). In total, 40 river water samples and 8 effluent samples were collected during October 2005 and June 2006.

While clofibric acid, dextropropoxyphene and sulfamethoxazole were not detected in the effluent samples, diclofenac, mefenamic acid and ibuprofen were detected in all effluent samples and in some of the river water samples. Diclofenac was detected in river water samples collected during both sampling periods but mefenamic acid, paracetamol and ibuprofen only in river water samples collected during one of the sampling periods; mefenamic acid (October 2005), paracetamol (June 2006) and ibuprofen (June 2006). Mefenamic acid was the most frequently detected pharmaceutical and was present in 50 % of the river water samples collected during October 2005 with a maximum concentration of  $0.5 \text{ ng L}^{-1}$ .

This concentration was 86 % higher than those measured by Hilton and Thomas (2003) in England and 67 % higher than those measured in the River Ebro in Spain (Gros et al. 2006; Ferreira da Silva et al. 2011). Mefenamic acid is not commonly analysed for, and to date studies involving the analysis of this compound have only been conducted in the U.K. (Thomas and Hilton 2004; Bound and Voulvoulis 2006; Hilton and Thomas

**Fig. 3** Comparison of the concentrations of individual pharmaceuticals detected in the River Thurso with estimated concentrations based on the concentrations found in WWTP effluents and river flow data



2003), Spain and Croatia (Gros et al. 2006), China (Zhao et al. 2008) and Japan (Hoshina et al. 2011). Diclofenac was detected in river samples collected during both sampling periods with a maximum concentration of  $1.9 \text{ ng L}^{-1}$ . The presence of diclofenac in natural water has been shown in most European countries including Spain and Croatia (Gros et al. 2006), UK (Thomas and Hilton 2004; Bound and Voulvoulis 2006; Hilton and Thomas 2003), Switzerland (Öllers et al. 2001) and France (Farre et al. 2001; Rabiet et al. 2006). Paracetamol was detected in 30 % of the samples with a maximum concentration of  $9.1 \text{ ng L}^{-1}$ , detected on the 21st of October 2005. The maximum concentrations of diclofenac and paracetamol were not found in the same sample. Of the pharmaceuticals detected, ibuprofen was the least frequently detected; being found in only one sample collected during the second sampling period.

The linearity of the relationship between pharmaceutical concentrations and the distance from the WWTP was evaluated for the four pharmaceuticals detected in the river. A linear relationship was found for mefenamic acid and paracetamol with 95 % confidence but not for diclofenac and ibuprofen. For paracetamol the concentration decreases as we go farther from the discharge point but for mefenamic acid it increased. Mefenamic acid was present in samples collected in the mouth of the river maybe due to the transformation of a conjugate to mefenamic acid when the river water comes into contact with the salt water.

#### *Estimated concentration in the River Thurso*

The concentration of the pharmaceuticals expected in the river were estimated based on the concentration of each pharmaceutical in the effluent sample obtained for each sampling day, the mean river flow data and WWTP 1 cumulative flow (24 h flow) during the sampling days. The river flow and WWTP flow data were obtained by from SEPA (Wheeler 2007, pers. comm.) and Scottish Water (Geddes 2007, pers. comm.).

When the concentrations of pharmaceuticals detected in the River Thurso are compared to their respective estimated concentrations (Fig. 3) we can see that the concentrations largely correspond. Estimated concentration and maximum measured Whitney and Kolmogorov-Smirnov tests because the data did not show a normal distribution. Significant differences were observed with both tests for ibuprofen, propranolol, trimethoprim but not for diclofenac and mefenamic acid. These results indicated that the concentrations of the most frequently detected pharmaceuticals (diclofenac and mefenamic acid) in effluents collected from WWTP 1 could be used to estimate their concentration in the river.

Further work is also needed to the understand degradation of these compounds under environmentally relevant conditions. For example, the results presented here were obtained at  $\sim 58.5^\circ \text{N}$ . At this latitude day-length and light quality (including UV) is highly seasonal and will thus introduce a

seasonal component onto degradation rates. The waters also typically have low nutrient levels, but high levels of dissolved organic carbon which will attenuate light penetration (Markager and Vincent 2000) and therefore limit degradation rates. These factors will influence half-lives and therefore the potential in situ ecotoxicological impact of pharmaceuticals.

## Conclusion

This study is the first to demonstrate the presence of human pharmaceuticals in the effluents arising from WWTPs in Scotland and that these represent direct source of human pharmaceuticals into the Scottish natural waters. The  $\text{ng L}^{-1}$  and  $\mu\text{g L}^{-1}$  concentrations observed add to the growing international body of evidence on the role of WWTPs in introducing a wide range of biologically active compound into natural waters.

Nine human pharmaceuticals (diclofenac, erythromycin, ibuprofen, mefenamic acid, paracetamol, propranolol, sulfamethoxazole, tamoxifen, trimethoprim and dextropropoxyphene) were detected WWTP effluent samples collected from a rural location in the north of Scotland. Maximum concentration ranged from  $7 \text{ ng L}^{-1}$  (sulfamethoxazole) to  $22.8 \mu\text{g L}^{-1}$  (paracetamol) with diclofenac and mefenamic acid being present in all of samples analysed at concentrations between 24.2 and  $927 \text{ ng L}^{-1}$  and 11.5 and  $22.8 \mu\text{g L}^{-1}$ .

Most work on the presence of pharmaceuticals in waste and natural waters has focused on urban areas i.e. those with high population density whereas this research study has been conducted in an area with low population density. The results of this study illustrate that even at these relatively low population densities (and low industrial intensity) human pharmaceuticals are present at in quantifiable levels in both WWTPs and receiving waters. Indeed two pharmaceuticals (diclofenac and mefenamic acid) were present in most of the samples investigated.

## References

- Andreozzi R, Raffaele M, Nicklas P (2003) Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. *Chemosphere* 50:1319–1330
- Ashton D, Hilton M, Thomas KV (2004) Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. *Sci Total Environ* 333:167–184
- Baker DR, Kasprzyk-Hordern B (2013) Spatial and temporal occurrence of pharmaceuticals and illicit drugs in the aqueous environment and during wastewater treatment: new developments. *Sci Total Environ* 454–455:442–456
- Barbara K, Dinsdale R, Guwy A (2008) The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK. *Water Res* 42:3498–3518



- Bendz D, Paxeus NA, Ginn TR, Loge FJ (2005) Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Hoje River in Sweden. *J Hazard Mater* 122:195–204
- Bound JP, Voulvoulis N (2006) Predicted and measured concentrations for selected pharmaceuticals in UK rivers: implications for risk assessment. *Water Res* 40:2885–2892
- Boxall AB, Fogg LA, Blackwell PA, Blackweel P, Kay P, Pemberton EJ, Croxford A (2004) Veterinary medicines in the environment. *Rev Environ Contam Toxicol* 180:1–91
- Brown KD, Kulis J, Thomson B, Chapman TH, Mawhinney DB (2006) Occurrence of antibiotics in hospital, residential, and dairy effluent, municipal wastewater, and the Rio Grande in New Mexico. *Sci Total Environ* 366:772–783
- Buser H, Müller MD (1998) Occurrence of the pharmaceutical drug clofibrac acid and the herbicide mecoprop in various Swiss lakes and in the North Sea. *Environ Sci Technol* 32:188–192
- Carballa M, Omil F, Lema JM, Llopart M, Garcia-Jares C, Rodriguez I, Gomez M, Ternes T (2004) Behavior of pharmaceuticals, cosmetics and hormones in a sewage treatment plant. *Water Res* 38:2918–2926
- Carballa M, Omil F, Ternes T, Lema JM (2007) Fate of pharmaceutical and personal care products (PPCPs) during anaerobic digestion of sewage sludge. *Water Res* 41:2139–2150
- Castiglioni S, Bagnati R, Fanelli R, Pomati F, Calamari D, Zuccato E (2006) Removal of pharmaceuticals in sewage treatment plants in Italy. *Environ Sci Technol* 40:357–363
- Corcoran J, Winter MJ, Tyler CR (2010) Pharmaceuticals in the aquatic environment: a critical review of the evidence for health effects in fish. *Crit Rev Toxicol* 40:287–304
- Dietrich DRE, Webb SFE, Petry TE (2002) Ed by Daniel R. Ed Dietrich. Hot spot pollutants: pharmaceuticals in the environment. *Toxicol Lett* 131:1–3
- Farre M, Ferrer I, Ginebreda A, Figueras M, Olivella L, Tirapu L, Vilanova M, Barcelo D (2001) Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with *Vibrio fischeri*. *J Chromatogr A* 938:187–197
- Ferreira da Silva B, Jelic A, López-Serna R, Mozeto AA, Petrovic M, Barcelo D (2011) Occurrence and distribution of pharmaceuticals in surface water, suspended solids and sediments of the Ebro river basin, Spain. *Chemosphere* 85:1331–1339
- Gagne F, Blaise C, Andre C (2006) Occurrence of pharmaceutical products in a municipal effluent and toxicity to rainbow trout (*Oncorhynchus mykiss*) hepatocytes. *Ecotoxicol Environ Saf* 64:329–336
- Garrison AW, Pope JD, Allen FR (1976) GC-MS analysis of organic compounds in domestic wastewater. In: Keith LH (ed) Identification and analysis of organic pollutants in water. *Ann Arbor Science, Michigan*, pp 517–556
- Geddes G (2007) Effluent flows, Scottish Water [personal communication] to Carolina Nebot
- Gomez MJ, Petrovic M, Fernandez-Alba AR, Barcelo D (2006) Determination of pharmaceuticals of various therapeutic classes by solid-phase extraction and liquid chromatography-tandem mass spectrometry analysis in hospital effluent wastewaters. *J Chromatogr A* 1114:224–233
- Gros M, Petrovic M, Barcelo D (2006) Development of a multi-residue analytical methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for screening and trace level determination of pharmaceuticals in surface and wastewaters. *Talanta* 70:678–690
- Heberer T, Fuhrmann B, Schmidt-Baumler K, Tsiipi D, Koutsouba V, Hiskia A (2001) Occurrence of pharmaceutical residues in sewage, river, ground and drinking water in Greece and Germany. In: Pharmaceuticals and personal care products in the environment: scientific and regulatory issues. by Jones-Lepp, T.L., et al. Washington, D.C., American Chemical Society; Oxford University Press distributor
- Hilton MJ, Thomas KV (2003) Determination of selected human pharmaceutical compounds in effluent and surface water samples by high-performance liquid chromatography-electrospray tandem mass spectrometry. *J Chromatogr A* 1015:129–141
- Hilton MJ, Thomas KV, Ashton D (2003) Targeted Monitoring Programme for Pharmaceuticals in the Aquatic Environment R&D Technical Report P6-012/06/TR. Environment Agency, Bristol
- Hoshina K, Horiyama S, Matsunaga H, Haginaka J (2011) Simultaneous determination of non-steroidal anti-inflammatory drugs in river water samples by liquid chromatography–tandem mass spectrometry using molecularly imprinted polymers as a pretreatment column. *J Pharm Biomed Anal* 55:916–922
- Jones OAH, Voulvoulis N, Lester JN (2007) The occurrence and removal of selected pharmaceutical compounds in a sewage treatment works utilising activated sludge treatment. *Environ Pollut* 145:738–744
- Kasprzyk-Hordem B, Dinsdale RM, Guwy AJ (2008) The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK. *Water Res* 42:3498–3518
- Kemper N (2008) Veterinary antibiotics in the aquatic and terrestrial environment. *Ecol Indic* 8:1–13
- Kools SAE, Boxall ABA, Moltmann JF, Bryning G, Koschorreck J, Knacker T (2008) A ranking of European veterinary medicines based on environmental risks. *Integr Environ Assess Manage* 4:399–408
- Kümmerer K (2008) Pharmaceuticals in the environment: sources, fate, effects and risks, 3rd edn. Springer, Berlin
- Kümmerer K (2009) The presence of pharmaceuticals in the environment due to human use—present knowledge and future challenges. *J Environ Manage* 90:2354–2366
- Lindberg RH, Olofsson U, Rendahl P, Johansson MI, Tysklind M, Andersson BAV (2006) Behavior of fluoroquinolones and trimethoprim during mechanical, chemical, and active sludge treatment of sewage water and digestion of sludge. *Environ Sci Technol* 40:1042–1048
- Markager S, Vincent WR (2000) Spectral light attenuation and the absorption of UV and blue light in natural waters. *Limnol Oceanogr* 45(3):642–650
- Maurer M, Escher BI, Richle P, Schaffner C, Alder AC (2007) Elimination of  $\beta$ -blockers in sewage treatment plants. *Water Res* 41:1614–1622
- Metcalfe CD, Koenig BG, Bennie DT, Servos M, Ternes TA, Hirsch R (2003) Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants. *Environ Toxicol Chem* 22:2872–2880
- Miao X, Metcalfe CD (2003) Determination of pharmaceuticals in aqueous samples using positive and negative voltage switching microbore liquid chromatography/electrospray ionization tandem mass spectrometry. *J Mass Spectrom* 38:27–34
- Moldovan Z (2006) Occurrences of pharmaceutical and personal care products as micropollutants in rivers from Romania. *Chemosphere* 64:1808–1817
- Nakada N, Tanishima T, Shinohara H, Kiri K, Takada H (2006) Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment. *Water Res* 40:3297–3303
- Nakada N, Shinohara H, Murata A, Kiri K, Managaki S, Sato N, Takada H (2007) Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. *Water Res* 41:4373–4382
- National Services Scotland (2014) Prescribing & Medicines: Prescription Cost Analysis Financial Year 2013/14. Publication date – 24 June 2014. Information Services Division. NHS National Services

- Scotland. <https://isdscotland.scot.nhs.uk/Health-Topics/Prescribingand-Medicines/Publications/2014-06-24/2014-06-24-Prescribing-PrescriptionCostAnalysis-Summary.pdf>. Accessed June 2014
- Nebot C, Gibb SW, Boyd KG (2007) Quantification of human pharmaceuticals in water samples by high performance liquid chromatography–tandem mass spectrometry. *Anal Chim Acta* 598:87–94
- Öllers S, Singer HP, Fassler P, Muller SR (2001) Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at the low-ng/l level in surface and waste water. *J Chromatogr A* 911: 225–234
- Rabiet M, Togola A, Brissaud F, Seidel JL, Budzinski H, Elbaz-Poulichet F (2006) Consequences of treated water recycling as regards pharmaceuticals and drugs in surface and ground waters of a medium-sized Mediterranean catchment. *Environ Sci Technol* 40:5282–5288
- Roberts PH, Thomas KV (2006) The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. *Sci Total Environ* 356:143–153
- Sanderson H, Laird B, Pope L, Brain R, Wilson C, Johnson D, Bryning G, Peregrine AS, Boxall A, Solomon K (2007) Assessment of the environmental fate and effects of ivermectin in aquatic mesocosms. *Aquat Toxicol* 85:229–240
- Sarmah AK, Meyer MT, Boxall ABA (2006) A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment. *Chemosphere* 65:725–759
- SEPA (2007) Scottish Environment Protection Agency Thurso at Halkirk [Online] Date. [http://www.nwl.ac.uk/ih/nrfa/station\\_summaries/097/002.html](http://www.nwl.ac.uk/ih/nrfa/station_summaries/097/002.html). Accessed 2008
- Sui Q, Wang B, Zhao W, Huang J, Yu G, Deng S, Zhaofu Q, Lu S (2012) Identification of priority pharmaceuticals in the water environment of China. *Chemosphere* 89:280–286
- Ternes TA (1998) Occurrence of drugs in German sewage treatment plants and rivers. *Water Res* 32:3245–3260
- Ternes T, Bonerz M, Schmidt T (2001) Determination of neutral pharmaceuticals in wastewater and rivers by liquid chromatography–electrospray tandem mass spectrometry. *J Chromatogr A* 938: 175–185
- The Office for National Statistic (2013) Population Estimates for UK, England and Wales, Scotland and Northern Ireland, Mid-2013 [Online] Date. <http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk-england-and-wales-scotland-and-northern-ireland/2013/index.html>. Accessed August 2014
- Thomas KV, Hilton MJ (2004) The occurrence of selected human pharmaceutical compounds in UK estuaries. *Mar Pollut Bull* 49:436–444
- Weigel S, Kuhlmann J, Huhnerfuss H (2002) Drugs and personal care products as ubiquitous pollutants: occurrence and distribution of clofibric acid, caffeine and DEET in the North Sea. *Sci Total Environ* 295:131–141
- Wheeler C (2007) River Thurso rainfall data, Scottish Environment Protection Agency [personal communication] to Carolina Nebot
- Zhao X, Metcalfe CD (2008) Characterizing and compensating for matrix effects using atmospheric pressure chemical ionization liquid chromatography–tandem mass spectrometry: analysis of neutral pharmaceuticals in municipal wastewater. *Anal Chem* 80:2010–2017
- Zhao JL, Ying GG, Liu YS, Chen F, Yang JF, Wang L (2010) Occurrence and risks of triclosan and triclocarban in the Pearl River system, South China: from source to the receiving environment. *J Hazard Mater* 179:215–222
- Zuccato E, Castiglioni S, Fanelli R, Bagnati R, Reitano G, Calamari D (2004) Risk related to the discharge of pharmaceuticals in the environment: further research is needed. In *pharmaceuticals in the Environment* Second edition edn. ed. by Springer-Verlag
- Zuccato E, Castiglioni S, Fanelli R (2005) Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. *J Hazard Mater* 122:205–209
- Zuccato E, Castiglioni S, Bagnati R, Chiabrando C, Grassi P, Fanelli R (2008) Illicit drugs, a novel group of environmental contaminants. *Water Res* 42:961–968